BPC-157 + TB-500 + GHK-Cu (70mg Blend)

This item is a three-component blend supplied in a single vial. Each component has its own literature and its own proposed mechanism, and the blend has none of its own — no study characterises this particular combination, so the components must be considered separately.

BPC-157 is a pentadecapeptide associated with VEGFR2-linked angiogenesis and reported across tendon, muscle and gastrointestinal injury models. TB-500 corresponds to the actin-binding region of thymosin beta-4; its proposed mechanism is actin sequestration and the resulting effects on cell migration and cytoskeletal remodelling. GHK-Cu is a copper-carrying tripeptide studied for effects on matrix protein expression and for its role as a copper delivery vehicle to enzymatic sites.

The one interaction worth noting experimentally is copper. GHK-Cu introduces a redox-active metal into the same solution as two peptides, and copper-catalysed oxidation is a known degradation route for peptides in solution. Reconstituted working stability for a blend of this composition should not be assumed equal to that of the components alone.

Findings below are drawn from published preclinical and clinical work and are presented for research context only.

• BPC-157. Rodent models report accelerated tendon, ligament and mucosal healing, with VEGFR2-associated angiogenesis as the leading mechanistic account.

• TB-500 / thymosin beta-4. The parent protein is an actin-sequestering peptide with a literature covering cell migration, corneal and dermal wound models, and cardiac repair.

• GHK-Cu. Reported to influence extracellular matrix protein expression and to act as a copper carrier; the copper complex, not the free tripeptide, is the active species in most reported systems.

• No blend-level data. No published study characterises this three-component combination. Additivity, synergy and interaction are all unestablished.

• Solution chemistry. Copper is redox-active and can catalyse oxidative degradation of peptides in solution. Working stability for the blend warrants independent verification.

This section describes laboratory handling. It is not clinical guidance, and no safety claim for human or veterinary administration is made or implied.

• Supplied lyophilized. Reconstituted peptide solutions have materially shorter working stability than the dry powder — prepare working aliquots and avoid repeated freeze-thaw cycles.

• Handle as a research chemical of undetermined hazard. Use gloves, eye protection and a laboratory coat.

• Storage temperature and, where applicable, reconstitution conditions are stated on the item specification sheet and the lot Certificate of Analysis, which take precedence over general guidance.

• Dispose of unused material and consumables in accordance with the institutional chemical waste policy.

• This blend contains a redox-active copper complex alongside two peptides. Copper can catalyse oxidative degradation in solution, so reconstituted working stability should not be assumed equal to that of the individual components.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement.

This is a three-component research blend of BPC-157, TB-500 and GHK-Cu supplied in a single vial. Component quantities are recorded on the lot Certificate of Analysis; the blend carries no single molecular formula.

Each component has an independent literature in tissue repair, but no study characterises this combination. Any account of the blend's behaviour is inference from the components.

The presence of a redox-active copper complex alongside two peptides is a solution-chemistry consideration for reconstituted working stability.

1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).

2. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495.

3. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025;15:30071.

4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619.

5. Zeng PM, Sun XY, Li Y, Wu WD, Huang J, Cao DD, et al. Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem Cell Reports. 2025;20(9):102601.

6. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.

7. Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533.

8. Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61.